GALT

$3.47+3.58%visit website

GALECTIN THERAPEUTICS INC

Market Cap

$350M

Live price × SEC shares (Aug 6, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.54

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	2,611	1,933	2,231	2,135	8,910
Total operating expenses	4,198	3,365	4,077	3,982	15,622
Operating income	(4,198)	(3,365)	(4,077)	(3,982)	(15,622)
Interest expense	1,820	1,939	1,988	2,004	7,751
Net income	(8,184)	(5,500)	(5,046)	(9,113)	(27,843)
EPS (basic) ($)	(0.13)		(0.08)	(0.14)	(0.43)
EPS (diluted) ($)	(0.13)		(0.08)	(0.14)	(0.43)
Weighted avg. shares (basic)	64,205		65,782	65,875
Weighted avg. shares (diluted)	64,205		65,782	65,875

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

13 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 14, 2026 accepted 11:55 AM ET	2.02Earnings release	Document SEC ↗
Aug 4, 2026 accepted 11:50 AM ET	3.02Unregistered equity sale	Document SEC ↗
Jun 23, 2026 accepted 11:51 AM ET	7.01Reg FD disclosure	Document SEC ↗
May 15, 2026 accepted 11:50 AM ET	2.02Earnings release	Document SEC ↗
Mar 31, 2026 accepted 11:55 AM ET	2.02Earnings release	Document SEC ↗
Mar 17, 2026 accepted 11:50 AM ET	5.02Officer / director change	Document SEC ↗
Jan 21, 2026 accepted 10:01 PM ET	5.02Officer / director change	Document SEC ↗
Jan 12, 2026 accepted 10:00 PM ET	5.02Officer / director change	Document SEC ↗
Dec 19, 2025 accepted 12:55 PM ET	1.01Material agreement	Document SEC ↗
Dec 8, 2025 accepted 1:00 PM ET	5.07Shareholder vote	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

44%

W/W -12.9pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-07-14	2026-07-16	Jamil Khurram	Chief Medical Officer	Sale	16.3K	$5.13	$83K	0	View
2026-06-29	2026-06-30	Shlevin Harold H.	Director	Sale	22.3K	$5.04	$112K	6,500	View
2026-06-29	2026-06-30	Jamil Khurram	Chief Medical Officer	Sale	47.5K	$5.04	$239K	0	View
2026-06-26	2026-06-30	Jamil Khurram	Chief Medical Officer	Sale	4,570	$5.00	$23K	0	View
2026-06-26	2026-06-30	Shlevin Harold H.	Director	Sale	7,732	$5.00	$39K	6,500	View

1–5 of 12

1 / 3

Recent News

Galectin Therapeutics stock: AASLD presentations spotlight belapectin

ad-hoc-news.de · 2026-11-05

Galectin Therapeutics (GALT) Stock Forecast & Analyst Ratings

Moomoo · 2026-11-01

Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - What's Next?

MarketBeat · 2026-10-24

Galectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average - Here's Why

MarketBeat · 2026-10-16

Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - Here's Why

MarketBeat · 2026-10-08

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

Yahoo · 2026-10-06

Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical

SeekingAlpha · 2026-10-06

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Yahoo Finance · 2026-09-10

A drug company will present in New York Sept. 14. Galectin will meet investors there.

Stock Titan · 2026-09-10

Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight

Yahoo Finance · 2026-08-24

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update

Yahoo Finance · 2026-08-14

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Yahoo Finance · 2026-08-04

Should I buy Galectin Therapeutics (GALT)

Zacks Investment Research · 2026-06-24

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Yahoo Finance · 2026-06-23

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial

Stocktwits · 2026-06-23

Informational purposes only, not investment advice.

GALT

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

GALECTIN THERAPEUTICS INC (GALT)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-07-14	Jamil Khurram	S	16,250	$83,284.5
2026-06-29	Shlevin Harold H.	S	22,268	$112,230.72
2026-06-29	Jamil Khurram	S	47,467	$239,233.68
2026-06-26	Jamil Khurram	S	2,533	$12,665
2026-06-26	Jamil Khurram	S	2,037	$10,185